Compare LGO & KRRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LGO | KRRO |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 101.1M |
| IPO Year | 2007 | 2019 |
| Metric | LGO | KRRO |
|---|---|---|
| Price | $1.34 | $12.31 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $3.40 | ★ $54.60 |
| AVG Volume (30 Days) | ★ 1.0M | 307.3K |
| Earning Date | 11-12-2025 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $111,884,000.00 | $7,371,000.00 |
| Revenue This Year | N/A | $145.49 |
| Revenue Next Year | $53.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.85 | $5.20 |
| 52 Week High | $2.70 | $55.89 |
| Indicator | LGO | KRRO |
|---|---|---|
| Relative Strength Index (RSI) | 57.49 | 63.53 |
| Support Level | $1.20 | $9.88 |
| Resistance Level | $1.40 | $14.94 |
| Average True Range (ATR) | 0.10 | 1.05 |
| MACD | -0.01 | 0.41 |
| Stochastic Oscillator | 44.10 | 60.34 |
Largo Inc is committed to the production and supply of high-quality vanadium products. The company is also focused on the advancement of renewable energy storage solutions through Largo Clean Energy and its vanadium redox flow battery technology. The Company is engaged in the mining, exploration, and development of mineral properties, predominantly in Brazil, through which it produces and supplies vanadium products VPURE Flake, VPURE+ Flake, and VPURE+ Powder. The company has operating segments: sales & trading, mine properties, which generates key revenue, corporate, exploration and evaluation properties, Clean Energy, and Largo Physical Vanadium.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.